Imprimis Pharma (IMMY) Reports Q3 Loss of $0.29/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Dow futures up on UnitedHealth boost; bond yields, Mideast tensions weigh
- UnitedHealth to take up to $1.6 billion hit from Change Healthcare hack this year
- Morgan Stanley's profit rises as investment banking rebounds
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- Stocks sag, dollar up as 'higher for longer' rate view takes root
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
Imprimis Pharmaceuticals Announces Third Quarter 2016 Financial Results
November 14, 2016 4:05 PM ESTSAN DIEGO, Nov. 14, 2016 /PRNewswire/ --Â Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the production and dispensing of high quality innovative compounded medications, today reported financial results for the third quarter 2016.
Recent Highlights:
Revenue of $4.9 million in the third quarter of 2016, up 81% compared to revenue of $2.7 million reported in the same quarter a year ago... More
